APR Applied Pharma Research S.A. and Labtec GmbH Announce Ondansetron Oral Dispersible Film (“ODF”) is Now Available for Licensing in Europe and Selected Non European ountries, after Having Received Marketing Authorization in Most Countries of Europe

BALERNA, Switzerland--(BUSINESS WIRE)--APR and Labtec have regained the marketing and commercialization rights of Ondansetron Oral Dispersible Film (“ODF”) together with the brand name “Setofilm®” after the termination of the former license agreement with the French Company BioAlliance which has refocused its activities towards other types of products. Ondansetron ODF is approved in 16 European countries and is ready to be marketed. APR and Labtec are in a position to offer marketing and commercialization rights for Ondansetron ODF in Europe and selected Non-European countries, either through global, regional or local license agreements.